HIGHLIGHTS
- who: Ruzhen Li et al. from the Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China have published the research work: IMP4 Silencing Inhibits the Malignancy of Lung Adenocarcinoma via ERK Pathway, in the Journal: Journal of Oncology of 22/Oct/2022
- what: The authors showed that IMP4 could promote the progression of LUAD through activating the ERK pathway. The authors demonstrated that IMP4 dramatically increased glucose uptake, lactate generation, and ATP synthesis in LUAD cells and tumour tissues, suggesting that IMP4 could enhance glycolysis in LUAD. The study . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.